araag2/HINT huggingface dataset:
Clinical trial NCT01259193 (phase 2, status: unknown status)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib and zoledronic acid
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Hepatocellular carcinoma confirmed with pathology or identified with radiological
             images with typical features

          -  patient with unresectable primary hepatocellular carcinoma

          -  Child-Pugh Class A or B, score ≤ 7

          -  ECOG score 0-2

          -  Expected survival time not less than 12 weeks

          -  At least one tumor nodule with one uni-dimension of ≥ 1 cm

          -  Peripheral platelet of or more than 50×10(9)/L

          -  Peripheral hemoglobin of or more than 85g/L

          -  Peripheral albumen of or more than 28g/L

          -  Total bilirubin ≤3.0mg/dl

          -  ALT and AST ≤ 5.0 x the upper limit of normal

          -  Serum amylase ≤ 1.5x the upper limit of normal

          -  Serum creatinine ≤ 1.5x upper limit of normal

          -  PT-INR<2.3 or PT prolong no more than 4s of normal

        Exclusion Criteria:

          -  Congestive heart failure > NYHA class 2

          -  History of active coronary disease( except myocardial infarction more than 6 months
             ago)

          -  Receive anti-arrhythmia treatment(except β-receptor blocker,calcium channel blocker
             and digoxin)

          -  uncontrollable hypertension

          -  Active clinically serious infections (> 2 NCI-CTC Version 3.0)

          -  History of HIV infection

          -  Inclined to hemorrhage or active hemorrhage with 1 month

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in this study

          -  Pregnant or breast-feeding.Women of childbearing potential must have a negative
             pregnancy test performed within 7 days prior to enrolling in this portion of the study

          -  Known or suspected allergy to any agent given in association with this trial

          -  Concomitant anti-cancer therapy (except immunotherapy and Chinese traditional
             treatment)

          -  Surgical operation within 4 weeks prior to enrolling in this portion of the study
Clinical trial NCT00458601 (phase 2, status: completed)
Conditions: malignant glioma
ICD codes: R18.0, C17.3, G21.0, J91.0, C05.2, C10.0, C16.0
Drugs: cdx-110 with gm-csf, temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.

          -  Gross total resection followed by conventional chemoradiation therapy without
             progression of disease.

        Exclusion Criteria:

          -  Presence of diffuse leptomeningeal disease or gliomatosis cerebri.

          -  Systemic corticosteroid therapy > 2 mg of dexamethasone or equivalent (as defined by
             the investigator) per day at study enrollment.

          -  Patients who have undergone stereotactic radiosurgery prior to or following surgical
             resection, or the placement of Gliadel® Wafers.

          -  Known allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a
             history of anaphylactic reactions to shellfish proteins.
Clinical trial NCT00702585 (phase 2, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: org 36286, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Wish to conceive;

          -  Oligomenorrhea (cycle length >=41 days) or amenorrhea (no menstrual cycle for >6
             months);

          -  Body Mass Index (BMI) >=18 and <=32 kg/m^2;

          -  Serum FSH levels within normal limits (1-10 IU/L);

          -  Normal serum prolactin and thyroid stimulating hormone (TSH) levels;

          -  Progestagen induced withdrawal bleeding or spontaneous menstrual bleeding;

        Exclusion Criteria:

          -  Tumours of the ovary, breast, uterus, pituitary or hypothalamus;

          -  Pregnancy or lactation;

          -  Undiagnosed vaginal bleeding;

          -  Ovarian cysts or enlarged ovaries not related to polycystic ovarian disease (PCOD);

          -  Any ovarian and/or abdominal abnormality interfering with ultrasound examination;

          -  Malformations of the sexual organs incompatible with pregnancy;

          -  Clomiphene resistance with documented anovulation (treated with 150 mg clomiphene for
             five days and no ovulation);

          -  Treatment with metformin, gonadotropins, or GnRH analogs within 90 days prior to the
             start of Org 36286 treatment;

          -  Treatment with clomiphene citrate within 42 days prior to the start of Org 36286
             treatment;

          -  Alcohol or drug abuse within the 12 months preceding signing of informed consent;

          -  Any clinically relevant abnormal laboratory value;

          -  Hypersensitivity to any of the substances in Org 36286;

          -  Hypersensitivity to Orgalutran® or any of its components;

          -  Use of any investigational drugs during 90 days before screening or previous
             participation in this trial.
Clinical trial NCT00570765 (phase 2, status: completed)
Conditions: liver cirrhosis, biliary
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: placebo, obeticholic acid (oca)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)[C@]([H])(CC)[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Female participants must be postmenopausal, surgically sterile, or if premenopausal,
             be prepared to use 1 effective method of contraception with all sexual partners during
             the study and for 14 days after the end of dosing.

          -  Male participants must be prepared to use 1 effective method of contraception with all
             sexual partners during the study during the study unless they had a prior vasectomy.

          -  Proven or likely PBC, as demonstrated by the participant presenting with at least 2 of
             the following 3 diagnostic factors:

          -  History of increased alkaline phosphatase (ALP) levels for at least 6 months;

          -  Positive antimitochondrial antibody titer (>1:40 titer on immunofluorescence or M2
             positive by enzyme-linked immunosorbent assay) or PBC-specific antinuclear antibodies
             (antinuclear dot and nuclear rim positive);

          -  Liver biopsy consistent with PBC

          -  Screening ALP level between 1.5 and 10 × upper limit of normal (ULN).

        Exclusion Criteria:

          -  Administration of the following drugs at any time during the 3 months prior to
             screening for the study: ursodeoxycholic acid, colchicine, methotrexate, azathioprine,
             or systemic corticosteroids.

          -  Screening conjugated (direct) bilirubin >2 × ULN.

          -  Screening alanine aminotransferase or aspartate aminotransferase >5 × ULN.

          -  Screening serum creatinine >133 micromoles/liter (1.5 mg/deciliter).

        History or presence of hepatic decompensation (for example, variceal bleeds,
        encephalopathy, or poorly controlled ascites).

          -  History or presence of other concomitant liver diseases including hepatitis due to
             hepatitis B or C virus infection, primary sclerosing cholangitis, alcoholic liver
             disease, definite autoimmune liver disease or biopsy proven nonalcoholic
             steatohepatitis.

          -  Pregnancy.
Clinical trial NCT01393158 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: apremilast
SMILES: [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Disease severity of Moderate, Severe, or Very Severe by Investigator Global
             Assessment.

          -  Disease severity must be greater than or equal to 6 on the Rajka-Langeland Severity
             Scoring system corresponding to moderate-severe disease.

          -  Baseline EASI score must be greater than or equal to 11. A previous validation study
             for the EASI scoring system revealed patients with moderate to very severe disease had
             mean EASI scores ranging from 11-30.

          -  Candidate for, or previously on systemic therapy, including cyclosporine,
             methotrexate, or other immunosuppressant and treatment with ultraviolet light.
             Specifically, subjects are considered candidates for systemic therapy when their
             disease is not adequately controlled using topical therapies or side-effects prevent
             the further safe use of topical therapies.

          -  Subjects must meet the washout requirements

        Exclusion Criteria:

          -  History of active mycobacterial infection with any species (including Mycobacterium
             tuberculosis) within 3 years prior to screening visit. Subjects with Mycobacterium
             tuberculosis infection more than 3 years prior to screening visit are allowed if
             successful treatment was completed at least 3 years prior to randomization and is
             documented and available for verification.

          -  At least 3 major bacterial infections resulting in hospitalization and/or requiring
             intravenous antibiotic treatment within the past 2 years.

          -  Clinically significant abnormality on the chest X-ray (CXR) at screening. Chest X-rays
             performed within 3 months prior to start of study drug are acceptable.

          -  Use of any investigational medication within 4 weeks prior to start of study drug or 5
             pharmacokinetic/pharmacodynamic half-lives (whichever is longer).

          -  Any clinically significant abnormality on 12-lead ECG (electrocardiogram) at
             screening.

          -  History of congenital or acquired immunodeficiency (e.g., Common Variable
             Immunodeficiency [CVID]).

          -  Hepatitis B surface antigen positive or Hepatitis B core antibody positive at
             screening.

          -  History of Human Immunodeficiency Virus (HIV) infection.

          -  Antibodies to Hepatitis C at screening.

          -  History of squamous cell carcinoma of the skin and thin melanoma.

          -  Systemic corticosteroid-dependent asthma.

          -  Active infection of any type at the time of enrollment.
Clinical trial NCT00284154 (phase 2, status: completed)
Conditions: carcinoma, small cell, lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: vinflunine
SMILES: CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Small cell lung cancer with progression after one previous chemotherapy or
             chemotherapy/radiation therapy regimen

          -  Measurable or evaluable disease

          -  Able to perform activities of daily living with minimal assistance

          -  Adequate hematological, liver, and kidney function

          -  Must give written informed consent prior to entry

        Exclusion Criteria:

          -  CNS involvement

          -  Serious active infection or underlying medical condition

          -  Significant history of uncontrolled cardiac disease
Clinical trial NCT00405938 (phase 2, status: completed)
Conditions: breast cancer, breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bevacizumab, anastrozole, fulvestrant
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal breast cancer (adenocarcinoma) estrogen (ER)and/or progesterone (PR)
             receptor positive that is locally advanced or locally recurrent and not able to be
             surgically removed OR with measurable and/or disease that is able to be assessed
             including isolated bone metastasis

          -  Female patients 18 years or older

          -  Documentation of ER+ and/or PR+

          -  No prior chemotherapy or hormone therapy for metastatic breast cancer or inoperable
             breast cancer that is locally recurrent or locally advanced

          -  Measurable or evaluable disease

          -  Radiation therapy to painful bone lesions or impending fractures is allowed as long as
             there is measurable or evaluable disease outside the radiated area.

          -  Must have adequate bone marrow, renal and liver function

          -  Patients receiving prior treatment with an anthracycline based chemotherapy must have
             a normal left ventricle ejection fraction

        Exclusion Criteria:

          -  No metastatic disease to the Central Nervous System

          -  No history of myocardial infarction (MI), stroke or transient ischemic attacks in the
             last 6 months

          -  No symptoms of peripheral vascular disease

          -  No history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess
             in the past 6 months

          -  No known hypersensitivity to phosphate, trehalose or polysorbate

          -  No serious non-healing wound, ulcer or bone fracture

          -  No uncontrolled high blood pressure or history of hypertensive crisis

          -  No New York Hear Association class II congestive heart failure

          -  No extensive cancer involvement of the liver or lungs

          -  No history of significant psychiatric disorders

          -  No significant vascular disease

        There are additional inclusion/exclusion criteria. The study center will determine if you
        meet all of the criteria. If you do not qualify for the trial, study personnel will explain
        the reasons. If you do qualify, study personnel will explain the trial in detail and answer
        any questions you may have. You can then decide if you wish to participate.
Clinical trial NCT00112437 (phase 2, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: odanacatib, odanacatib, odanacatib, odanacatib, placebo
SMILES: CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal for 5 or more years, defined as no menses for at least 5 years OR at
             least 5 years status post bilateral oophorectomy

          -  Bone mineral density T-score at the hip or spine of -2.0 or less

          -  Spinal anatomy suitable for dual-energy x-ray absorptiometry (DXA). At the lumbar
             spine, there is no evidence of vertebral fracture in at least 3 vertebrae in the L1 to
             L4 region on baseline spine films. (Significant scoliosis, bony trauma, degenerative
             joint disease, and sequelae of orthopedic procedures that result in anatomy that is
             unsuitable for accurate bone densitometry must be absent from the lumbar spine.)

          -  At least one hip must be evaluable by DXA (e.g., contain no hardware from orthopedic
             procedures)

          -  In a state of general health allowing for successful completion of the trial

          -  Agreement to not use any medications to treat osteoporosis during the study

        Exclusion Criteria:

          -  History of prior osteoporotic fracture (unless declined treatment with or was
             ineligible for osteoporosis therapy)

          -  Past treatment with osteoporosis medications, steroids, hormone replacement, as well
             as various other medications that affect bone may be exclusionary. (Different
             exclusion criteria apply to each bone active drug. For example, any prior use of
             intravenous (IV) bisphosphonates is not permitted. By contrast, prior use of hormone
             replacement for several years is permitted if it has not occurred within the past 6
             months. Please ask the study doctor for details)

          -  Significant clinical or laboratory abnormalities at the screening visit for the study
             that, in the opinion of the investigator, could complicate interpretation of the study
             results or pose additional risk to the patient (for example, patients who are
             non-ambulatory should be excluded for this reason)
Clinical trial NCT00259857 (phase 2, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: alendronate
SMILES: COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O
Eligibility criteria:

        Eligibility Criteria:

          -  5-15 yrs of age

          -  Weighing 20 kg and more

          -  History of multiple fractures

          -  Tanner stage II or less

          -  Osteoporosis by DXA.

        Inclusion Criteria:

          -  Male and female children with a history of one or more atraumatic fractures, or
             evidence of one or more compression fractures on radiographs of the spine (reduction
             of >20 percent).

          -  Bone Mineral Density (BMD) determined by DXA sacn to confirm osteoporosis at a Z score
             greater than 2 SD (standard deviations) below the normal mean for age (Z score < -2
             SD).

          -  Parental consent (and patient assent after age 12 years) to participate in the study.

          -  Sexual development at: Tanner stage II or less (Prepubertal stage).

          -  Weight = 20 kg and more.

        Exclusion Criteria:

          -  History of severe gastritis or reflux.

          -  Abnormalities of the esophagus that delay emptying, such as strictures or achalasia

          -  Marked kyphoscoliosis or the inability to sit or stand for at least 30 minutes

          -  Hypersensitivity to bisphosphonates

          -  Uncorrected hypocalcemia

          -  History of gastric or duodenal ulcers

          -  Renal dysfunction as indicated by serum Cr >1.5 mg/dl.

          -  Liver dysfunction as indicated by serum SGPT > 2 times the upper limit for age or
             serum total bilirubin > 2.0 mg/dl.

          -  Diagnosis of osteogenesis imperfecta, a family history of osteogenesis imperfecta,
             blue sclerae or deafness.

          -  Diagnosis of active rickets or osteomalacia or serum bone alkaline phosphatase 2 times
             greater than normal for age.

          -  Pregnancy

          -  Anorexia Nervosa
Clinical trial NCT01103050 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: qav680 + cetirizine placebo, qav680 + cetirizine, cetirizine + qav680 placebo, qav680 placebo + cetirizine placebo
SMILES: OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with clinical history of intermittent allergic rhinitis with seasonal onset
             and offset of nasal allergy symptoms during each of the last two ragweed allergy
             seasons

          -  positive skin prick test to ragweed allergen within twelve months of screening

        Exclusion criteria:

          -  Use of any medication used to treat allergy (administered via any route), such as:
             pseudoephedrine, antihistamines, ipratropium bromide, cromoglycates, corticosteroids,
             immunotherapy or other antiinflammatory or immunosuppressive agents, or any other
             medication administered via the nasal or ocular routes)

          -  Within the last three years a recurrent history of acute or chronic bronchospastic
             disease including moderate-severe asthma or chronic obstructive pulmonary disease

          -  Nasal conditions such as nasal septal perforations,nasal polyps, sinus disease,
             chronic nasal obstruction

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00304135 (phase 2/phase 3, status: completed)
Conditions: extrahepatic bile duct cancer, gallbladder cancer, liver cancer
ICD codes: C24.0, D13.5, C23, D37.6, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: cisplatin, gemcitabine hydrochloride, oxaliplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of cancer of the biliary tract by 1 of the following methods:

               -  Histologic confirmation

               -  Stenosis of the biliary tract by MRI, CT scan, or ECHO

          -  Unresectable disease

          -  Amenable to radiotherapy

          -  No visceral metastases by imaging

               -  Hepatic adenopathies that can be included in a radiation field allowed

          -  No known ampulla of Vater or pancreatic cancer involving the biliary tract

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Creatinine < 1.5 mg/dL

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 75,000/mm^3

          -  Prothrombin time > 70%

          -  Bilirubin ≤ 2.9 mg/dL (after hepatic draining, if needed)

          -  No unstable angina

          -  No symptomatic cardiac insufficiency

          -  No other comorbidity that would preclude study therapy

          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the
             cervix

          -  No prior hydatid cyst or alveolar echinococciasis

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

          -  No recent biliary surgery

          -  No hepatic intra-arterial chemotherapy

          -  No prior anticancer therapy
Clinical trial NCT00494442 (phase 2, status: completed)
Conditions: ovarian neoplasm
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ku-0059436 (azd2281)(parp inhibitor), ku-0059436 (azd2281)(parp inhibitor)
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced ovarian cancer with positive BRCA1 or BRCA2 status

          -  Failed at least one prior chemotherapy

          -  In investigators opinion, no curative standard therapy exists

          -  Measurable disease

        Exclusion Criteria:

          -  Brain metastases

          -  Less than 28 days since last treatment used to treat the disease

          -  Considered a poor medical risk due to a serious uncontrolled disorder